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Abstract
Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis and the resulting fractures cause
signiﬁcant morbidity. Following initiation of oral glucocorticoids, rapid bone loss occurs, and fracture risk increases within a
few months in a dose-dependent manner. These adverse effects are due to inhibition of bone formation accompanied by an
early but transient increase in bone resorption. Multiple mechanisms underlie these changes in bone remodeling; direct
effects include upregulation of PPARγR2, increased expression of sclerostin and increased RANKL/OPG ratio, whilst
hypogonadism, altered renal and intestinal calcium handling, and reduced production of insulin-like growth factor 1 also
contribute. Fracture risk assessment should be performed as soon as possible after glucocorticoids are initiated and bone
protective therapy started promptly in individuals at high-risk, with calcium and vitamin D supplements where appropriate.
Oral bisphosphonates are currently regarded as ﬁrst line options on the grounds of their low cost. However, teriparatide has
been shown to be superior in its effects on BMD and vertebral fracture risk in glucocorticoid-treated individuals with
osteoporosis and should be considered as an alternative ﬁrst line option in high-risk patients.
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Introduction
Glucocorticoids are used in the treatment of a wide range of
diseases and it is estimated that 1–2% of the population is
receiving long-term glucocorticoid therapy [1–4]. The
adverse skeletal effects of glucocorticoid excess were ﬁrst
described over 80 years ago, and today glucocorticoid-
induced osteoporosis is the most common secondary cause
of osteoporosis. Research into the epidemiology, patho-
physiology and clinical management of glucocorticoid-
induced osteoporosis has produced substantial advances, yet
the condition remains under-recognized and under-treated.
This review focuses on recent developments in the ﬁeld and
their implications for clinical practice.
Epidemiology
Continuous oral glucocorticoid therapy is associated with
rapid bone loss and an increase in fracture risk that is seen
within 3–6 months of initiation and is dose-related. This
time course can be explained, at least in part, by the higher
doses of glucocorticoids and greater disease activity in the
early stages of treatment. Fracture risk remains elevated for
the duration of glucocorticoid therapy, but declines after its
withdrawal, although whether it reverts to baseline values is
unclear [5–8]. Vertebral fractures are particularly char-
acteristic of glucocorticoid-induced osteoporosis, although
the risk of non-vertebral fractures, including hip fractures, is
also increased.
Recent studies have conﬁrmed the predilection for ver-
tebral fracture, the dose-related increase in fracture risk,
and decline in fracture risk with longer duration or dis-
continuation of glucocorticoid therapy. Amiche et al con-
ducted a Bayesian meta-analysis of fracture risk associated
with oral glucocorticoid use, drawing on data from the
control groups of clinical trials [9]. In individuals who had
initiated glucocorticoid therapy in the last 6 months, the
annual incidence of vertebral fracture was 5.1% [95%
credible intervals (CrI) 2.8–8.2] and of non-vertebral
fracture, 2.5% [95% CrI 1.2–4.2]. For those with duration
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of glucocorticoid use ≥6 months, the corresponding ﬁgures
were 3.2% [95% CrI 1.8–5.0] and 3.0% [95% CrI 0.8–5.0].
Using a large administrative database, Balasubramanian
et al investigated the effects of initiating systemic (oral or
injected) glucocorticoid therapy on fracture risk in patients
with new-onset rheumatoid arthritis (mean age 49 years)
[10]. Fracture incidence rates were 5 to 9/1000 person
years at doses of <15 mg/day, 16 (11, 22.6) at doses
≥15 mg/day and 13.4 (10.7, 16.7) at cumulative doses
≥5400 mg. At 60-182 days after discontinuation of gluco-
corticoid therapy, fracture risk was 29% lower than in those
with ongoing use and by 12 months was similar to non-
glucocorticoid users.
The effects of inhaled or intravenous glucocorticoids on
fracture risk are less well documented. There is some evi-
dence that high doses of inhaled glucocorticoids may be
associated with increased fracture risk, although concurrent
use of oral glucocorticoids is often a confounding factor
[11–14]. In a large case control study from Denmark, no
increase in fracture risk was found in association with other
forms of topical steroids [15].
Variation in the severity of adverse effects of gluco-
corticoids, including bone loss, is well recognized but
poorly understood. Pre-receptor modulation of glucocorti-
coid activity by 11 beta-hydroxysteroid dehydrogenase
(11βHSD) enzymes, which interconvert inactive and active
cortisone/cortisol, may contribute to this variability through
the effects of pro-inﬂammatory cytokines [16, 17] and
genetic polymorphisms in the glucocorticoid receptor
gene [18].
Pathophysiology
Direct effects on bone
Glucocorticoid-induced osteoporosis is characterized by
decreased bone formation, with an additional early but
transient increase in bone resorption (Fig. 1). The initial
increase in remodeling rate is accompanied by reduced bone
formation at the level of the individual bone multicellular
unit (BMU), and this combination of increased bone turn-
over and a negative remodeling balance results in rapid
bone loss [19–23]. Subsequently, the decrease in bone
formation, both at tissue and BMU level, predominates
leading to a low turnover state. Direct effects of gluco-
corticoids on bone formation are mediated largely through
upregulation of peroxisome proliferator-activated receptor
gamma receptor 2 (PPARγ2) [24] and effects on the Wnt/β-
catenin signaling pathway [25, 26]. The former mechanism
favors the differentiation of pluripotent precursor cells to
adipocytes in preference to osteoblasts, resulting in
decreased numbers of osteoblasts. Increased expression of
sclerostin, which binds to the co-receptors for frizzled, Lrp4
and Lrp5, results in inhibition of Wnt sigalling leading to
reduced differentiation of osteoblast precursors to mature
osteoblasts and increased osteoblast and osteocyte apopto-
sis. The importance of sclerostin in mediating the effects of
glucocorticoids on bone formation is emphasized by the
demonstration, in mice with sclerostin deﬁciency, that bone
integrity is maintained in the presence of glucocorticoid
excess [27]. Furthermore, in a mouse model of
glucocorticoid-induced osteoporosis, treatment with an
antibody to sclerostin prevented the reduction in bone mass
and strength [28].
Glucocorticoids also have direct effects on bone resorp-
tion, increasing the production of macrophage colony sti-
mulating factor (M-CSF) and RANKL and decreasing
production of osteoprotegerin (OPG) by osteoblastic cells
and osteocytes, resulting in an increase both in the number
and activity of osteoclasts [29, 30]. This effect diminishes
with time, possibly as a result of the reduction in number of
osteoblasts and osteocytes. Finally, there is some evidence
from animal models that glucocorticoids affect osteocyte
morphology and mineralization [31].
Indirect effects on bone
Other mechanisms that may contribute to glucocorticoid-
induced bone loss through indirect effects on bone include
hypogonadism, reduced physical activity, increased renal
and intestinal losses of calcium, and reduced production of
growth hormone, insulin-like growth factor 1 (IGF1) and
IGF1 binding protein (IGF-BP) [32]. In addition, the
underlying diseases for which glucocorticoid therapy is
administered are often associated with increased inﬂam-
mation, which contributes to bone loss through increased
production of pro-inﬂammatory, pro-resorptive cytokines.
Whilst glucocorticoids suppress inﬂammation and hence
should mitigate the adverse effects of inﬂammation, disease
relapse despite therapy is associated with episodes of
increased bone resorption. Finally, glucocorticoid excess
has adverse effects on muscle mass and function, leading to
myopathy and increased risk of falls [33].
Changes in BMD and bone microarchitecture
Increased rates of bone loss in the hip, spine, and radius are
well documented in individuals treated with glucocorti-
coids. Data obtained from assessment of bone micro-
architecture using high-resolution peripheral computed
tomography (HRpQCT) are sparse. In a cross-sectional
study of 30 postmenopausal women who had received oral
glucocorticoids for longer than 3 months, despite similar
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areal BMD values to 60 control subjects, signiﬁcantly lower
total, cortical and trabecular volumetric BMD, thinner cor-
tices, increased trabecular separation and reduced trabecular
number were reported in the radius and tibia; whole bone
stiffness, assessed using ﬁnite element analysis, was also
signiﬁcantly reduced in comparison to the controls [34].
Although the patients and controls were generally well
matched, however, bisphosphonate use was signiﬁcantly
more common in the former (100% vs. 8.6%), so deﬁnite
attribution of the observed differences to glucocorticoid
therapy cannot be made.
Trabecular bone score (TBS) provides an indirect index
of trabecular bone architecture that can be obtained from
DXA images of the lumbar spine, and has predictive value
for fracture independent of BMD [35]. In 64 post-
menopausal women who had taken prednisolone in a dose
of ≥5 mg daily for >3 months, TBS was signiﬁcantly lower
than in a group of non-glucocorticoid treated controls,
although lumbar spine BMD T-scores were not signiﬁcantly
different [36]. Similar ﬁndings have been reported in 416
individuals on long-term glucocorticoids (≥5 mg daily for
3 months), the decrease in TBS being most marked in men
and in individuals with fracture [37]. These ﬁndings indi-
cate that glucocorticoids have adverse effects on spine bone
microarchitecture that are independent of BMD and which
may contribute to increased fracture risk.
Fracture risk assessment in individuals treated with
glucocorticoid-induced osteoporosis
There is evidence from a number of studies that fracture
occurs at a higher BMD in individuals receiving gluco-
corticoids than in non-glucocorticoid treated people
[38–40]. This independent effect of glucocorticoid therapy
on fracture risk may be due to several factors, including
increased falls risk and alterations in bone quality that are
not captured by BMD measurements.
Glucocorticoid therapy is included as a risk factor in the
FRAX fracture prediction algorithm as a dichotomous
variable. “Yes” is entered in the questionnaire if there is
current exposure to oral glucocorticoids or past exposure for
≥ 3 months at a dose of 5 mg/day or more of prednisolone or
equivalent. Using data from the UK General Research
Practice Database, Kanis et al have provided adjustments
that can be incorporated into the FRAX calculations to
adjust for different doses of glucocorticoids (Table 1) [41].
For daily doses of over 7.5 mg daily of prednisolone or
equivalent, greater upward adjustment of fracture prob-
ability may be required. It should be noted that the duration
of glucocorticoid therapy and cumulative dose are not
accommodated within the FRAX algorithm. In addition, the
use of total hip BMD in FRAX may result in under-
estimation of fracture risk in patients with differentially low
Fig. 1 Direct effects of glucocorticoids on bone
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spine BMD, although a correction for this discordance has
been proposed [42, 43]. A ﬁnal caveat is that the response to
treatment in glucocorticoid-treated individuals selected on
the basis of FRAX-derived fracture probability has not been
documented.
Assessment of fracture risk using FRAX is recom-
mended in several guidelines for the management of
glucocorticoid-induced osteoporosis, including the National
Osteoporosis Guideline Group (NOGG) guidance [44, 45],
the updated recommendations produced by the American
College of Rheumatology (ACR) [46] and guidelines pub-
lished by the International Osteoporosis Foundation (IOF)
and European Calciﬁed Tissues Society (ECTS) [47, 48].
However, FRAX can only be used in people age 40 years
and over; in children and young adults, fracture risk
assessment should be performed using BMD measurement,
together with consideration of other risk factors, particularly
previous fracture.
Management of glucocorticoid-induced
osteoporosis
Under-treatment of glucocorticoid-induced osteoporosis is
widely recognized [49, 50]. In a population-based study of
adults age ≥20 years, rates of BMD testing and prescription
of bone protective medication between 1998 and 2008 were
studied in individuals prescribed systemic glucocorticoids
for 90 days or longer [51]. Overall, in the ﬁrst six months
after initiation of glucocorticoid therapy only 6% had BMD
testing, 22% received therapy and 25% had both interven-
tions. Under-treatment was greatest in younger people and
men, and primary care physicians had lower prescription
rates than rheumatologists. Similar results have been
reported more recently using information from a national
public health-insurance database in France, with only 8%
undergoing BMD testing and prescription of calcium ±
vitamin D and bisphosphonates in 18 and 12% respectively
[52]. In a large cohort from Canada of men and women
aged 66 years or over who were initiating long-term glu-
cocorticoid therapy, Amiche et al reported that only 13%
were prescribed bone protective therapy [53]. The problem
of under-treatment is compounded by poor persistence with
bisphosphonate therapy, particularly in younger people,
those with co-morbidities, and those in whom BMD mea-
surements have not been made [54].
General measures
A number of life-style measures may mitigate the harmful
skeletal effects of glucocorticoids, although the evidence
base for this approach is weak and requires extrapolation
from studies in non-glucocorticoid treated individuals. Falls
risk should be assessed and preventive measures instituted
when appropriate. Exercise, tailored to the individual
patient, and good nutrition with adequate dietary calcium
intake should be advocated with avoidance of smoking and
alcohol abuse. Maintenance of an adequate vitamin D status
should also be advised.
Attention should be paid to keeping the dose of gluco-
corticoids to a minimum, with the use of steroid-sparing
drugs such as methotrexate or azathioprine or alternative
routes of administration (for example inhaled or topical)
where appropriate. Non-steroidal therapies should be used
when possible to maintain remission, once achieved.
However, it is also important to maintain suppression of the
underlying disease, since this will prevent the adverse
skeletal effects of inﬂammation and other effects of
increased disease activity.
Studies of the effects of calcium and/or vitamin D sup-
plementation on BMD in patients taking glucocorticoids
have produced conﬂicting results [55, 56]. However, cal-
cium and vitamin D supplements have been included in
most trials of bone protective therapy and should therefore
be used as an adjunct to treatment.
Pharmacological interventions
Regulatory approval of drugs to reduce fracture risk in
individuals taking glucocorticoids has been based on the
demonstration of similar changes in BMD to those
observed in postmenopausal osteoporosis and fracture has
been a secondary outcome. For this reason, evidence for
anti-fracture efﬁcacy of bone protective agents in
glucocorticoid-induced osteoporosis is less robust than that
for postmenopausal osteoporosis. In addition, there is
inevitable heterogeneity in glucocorticoid-treated trial
populations, with respect to age, underlying disease,
co-morbidities and co-medications, dose and duration of
glucocorticoid therapy and the timing of bone protective
therapy. Furthermore, the duration of most treatment stu-
dies has been relatively short and this, combined with
smaller trial populations, reduces the strength of the safety
database.
Table 1 Adjustment of FRAX-derived fracture probability according
to dose of glucocorticoids. Data from ref. [40]
Daily dose of
prednisolone (mg)
Average adjustment for
major osteoporotic
fracture probability
Average adjustment
for hip fracture
probability
<2.5 −20% −35%
2.5–7.5 None None
≥7.5a +15% +20a
aFor high doses of prednisolone, greater upward adjustment of fracture
risk may be appropriate
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Bisphosphonates
Bisphosphonates are the most commonly used drugs in the
management of glucocorticoid-induced osteoporosis. Oral
alendronate (5 or 10 mg daily or 70 mg once weekly) and
risedronate (5 mg daily or 35 mg once weekly), and intra-
venous zoledronic acid (5 mg once yearly by intravenous
infusion) are all approved for this indication. All have been
shown to have beneﬁcial effects on lumbar spine and hip
BMD in people treated with glucocorticoids [57–64] and for
alendronate and risedronate, there is also evidence from
safety or post hoc analyses for a reduction in the rate of
vertebral fractures [62, 63]. In the pivotal study of zole-
dronic acid, a non-inferiority BMD comparison with rise-
dronate, the fracture rate was too low to assess anti-fracture
efﬁcacy [64].
The number of non-vertebral and hip fractures has been
insufﬁcient in individual trials to assess an impact of
bisphosphonates. However, data from cohort studies provide
some evidence for efﬁcacy at these sites. In an observational
cohort study of women aged >65 years taking alendronate or
risedronate, Thomas et al. studied the baseline incidence of
clinical fractures in the ﬁrst three months after starting glu-
cocorticoid therapy and the fracture incidence in the fol-
lowing 12 months [65]. Compared to the baseline incidence,
both clinical vertebral and non-vertebral fracture incidence
were signiﬁcantly lower. Using the same database, Overton
et al studied the effects of bone protective therapy (bispho-
sphonates in 95.5%, denosumab or teriparatide in the
remaining 4.5%) in a large cohort of new glucocorticoid
users [66]. Treatment within the ﬁrst 90 days of gluco-
corticoid use was associated with a signiﬁcant reduction in
clinical fractures (including vertebral) of 48% at one year
and 32% at three years when compared with non-use.
Finally, in three matched cohorts derived from healthcare
administrative data from Ontario, Canada, Amiche et al.
reported that in individuals initiating long-term glucocorti-
coids, therapy within the ﬁrst six months with alendronate or
risedronate was associated with a decrease in incident hip
fracture (alendronate 0.49 (0.34, 0.69), risedronate 0.58
(0.36, 0.90) [53]. The results conﬁrmed a reduction in ver-
tebral fracture risk with etidronate, alendronate and rise-
dronate, but no decrease in risk of forearm or humerus
fractures for any bisphosphonate. The analysis was limited
to oral bisphosphonates and zoledronic acid was not con-
sidered. Overall, therefore, these studies would be consistent
with a beneﬁcial effect of bisphosphonates both on vertebral
and non-vertebral fracture, including hip fracture.
The safety proﬁle of bisphosphonates in glucocorticoid-
induced osteoporosis has been less well studied than in
postmenopausal osteoporosis because of the small number
of participants included and shorter duration of the trials.
Because of co-morbidities and co-medications, people
taking glucocorticoids may be more susceptible to side-
effects, for example upper gastrointestinal disorders, and
glucocorticoid therapy is a documented risk factor for
osteonecrosis of the jaw [67] and probably also for atypical
femoral fractures [68, 69]. Bisphosphonates should be used
with caution in premenopausal women with child bearing
potential, because of the ability of these drugs to cross the
placenta.
Teriparatide
The predominant role of reduced bone formation in
glucocorticoid-induced osteoporosis provides a rationale for
the use of anabolic agents in its treatment. In an active-
comparator controlled, randomized, double blind study the
effects of 18 months treatment with subcutaneous teripara-
tide, 20 µg/day, or oral alendronate 10 mg/day, were com-
pared in 428 men and women with glucocorticoid-induced
osteoporosis [70]. Teriparatide therapy resulted in sig-
niﬁcantly greater increases in spine and hip BMD and this
was seen in both premenopausal and postmenopausal
women and in men [71]. The magnitude of increase in
BMD was somewhat less than that seen in non-
glucocorticoid treated postmenopausal women in another
study [72], possibly as a result of the opposing actions of
intermittent PTH and glucocorticoids on osteoblastogenesis,
and osteoblast and osteocyte apoptosis [73–75].
Although fracture was not a primary end-point of the
study, signiﬁcantly fewer new vertebral fractures occurred
in the patients treated with teriparatide when compared to
those treated with alendronate (0.6% vs. 6.1%; p= 0.004).
The incidence of non-vertebral fractures was similar in the
two treatment groups. Results after 36 months of treatment
demonstrated a continued increase in spine and hip BMD in
the teriparatide treated group, with superiority over alen-
dronate at the 24 and 36 month time points [76]. A lower
incidence of new vertebral fractures was also seen in the
teriparatide group at 36 months (1.7% vs 7.7%, p= 0.007),
with a similar incidence of non-vertebral fractures in the
two groups. Interestingly, measurements of TBS in a sub-
population of this study demonstrated a signiﬁcant increase
after 36 months in teriparatide treated patients, but no sig-
niﬁcant change in those treated with alendronate [77].
Whilst the long duration of this study is unique amongst
treatment trials for glucocorticoid-induced osteoporosis, it
should be noted that the participant discontinuation rate at
36 months was 44%. With regard to safety, increased pre-
dose serum calcium levels were signiﬁcantly more common
in the teriparatide than alendronate treated group (21% vs.
7%), but no other concerns were identiﬁed
In a comparison of the effects of teriparatide and rise-
dronate in men treated with oral glucocorticoids for
≥3 months, signiﬁcantly greater increases in lumbar spine
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trabecular volumetric BMD were demonstrated in the
teriparatide-treated group at 18 months. In addition, ter-
iparatide was associated with signiﬁcantly greater
improvements in bone strength and stiffness at T12, mea-
sured using HRQCT-based ﬁnite element analysis [78].
These data, together with the results of the study reviewed
above, provide a rationale for the use of teriparatide as a
ﬁrst line option in some patients, particularly those at high
risk of vertebral fracture.
Teriparatide is contraindicated in pregnant and lactating
women. Women of childbearing potential should use
effective methods of contraception while on teriparatide
treatment.
Denosumab
At present, denosumab is not approved for use in
glucocorticoid-induced osteoporosis, although this is cur-
rently under consideration by some regulatory agencies. In a
Phase 3 randomized double blind active controlled trial of
adults taking ≥7.5 mg prednisone or equivalent daily,
treatment with denosumab, 60 mg once every 6 months by
subcutaneous injection, was associated with a signiﬁcantly
greater increase in lumbar spine BMD compared to rise-
dronate 5 mg daily over a 12 months treatment period [79].
This effect was seen both in patients initiating glucocorti-
coids and in those established on long-term therapy,
regardless of age, race, baseline BMD T-score, initial glu-
cocorticoid dose and menopausal status. To date the study
has only been reported in abstract form.
Guidelines for the management of glucocorticoid-
induced osteoporosis
National guidelines for the management of glucocorticoid-
induced osteoporosis have been produced by a number of
countries and updated guidelines have recently been
published from the US and UK. Most guidelines address
users of long-term (3 months) oral glucocorticoids, and
although the daily threshold dose varies it has generally
been between 5 and 7.5 mg daily of prednisolone or
equivalent. Treatment thresholds also vary; T-scores are
used in some and generally recognize the higher BMD at
which fracture occurs in glucocorticoid-treated indivi-
duals. The recent guidelines from the UK and US
emphasize the importance of starting bone protective
therapy early in high-risk individuals, because of the
rapidity with which bone loss and increased fracture risk
occur.
The recently updated ACR guideline deﬁnes three cate-
gories of fracture risk; high, moderate and low. In adults
aged ≥40 years, previous osteoporotic fracture, hip or spine
BMD T-score ≤ −2.5, or 10 year fracture probability of
≥20% (major osteoporotic fracture) or ≥3% (hip fracture)
are the criteria for high risk [45]. Moderate and low risk are
deﬁned solely on the basis of FRAX-derived fracture
probability (10–19% and >1 to ≤3% respectively for mod-
erate risk, <10% and ≤1% respectively for low risk). In
adults <40 years old, the criterion for high risk is a previous
osteoporotic fracture, whereas moderate and low risk are
deﬁned on the basis of BMD. Oral bisphosphonates are
recommended as the ﬁrst line option for individuals at
moderate or high risk, with intravenous bisphosphonates,
teriparatide, or denosumab in patients who are contra-
indicated or intolerant to oral bisphosphonates. NOGG, in
its 2017 update, takes a similar approach to risk assessment
with the use of dose-adjusted FRAX, but uses the UK
NOGG intervention thresholds as the basis for making
treatment decisions and does not include denosumab as a
treatment option [44, 45].
These recent guidelines emphasize the importance of
early intervention in high-risk individuals, advocate main-
tenance of adequate calcium intake and normal vitamin D
status, and stress the limited evidence base to support some
recommendations, particularly in younger adults. Compar-
ison of the cost-effectiveness of different treatments is
problematic because of the lack of fracture data, particularly
hip fracture, in clinical trials. The choice of oral bispho-
sphonates as a ﬁrst line option in both sets of guidelines is
based on their lower cost compared to either zoledronic acid
or teriparatide; nevertheless, in view of the superiority of
teriparatide vs. alendronate for BMD and vertebral fracture
outcomes, it has been suggested that teriparatide should be
considered as an alternative ﬁrst line option in those at
highest risk [80].
Conclusions
There have been signiﬁcant advances in our understanding
of the mechanisms by which glucocorticoids affect bone
and increase fracture risk. The clinical management of
glucocorticoid-induced osteoporosis, however, remains
suboptimal despite the development of more sophisticated
approaches to fracture risk assessment and the availability
of several effective treatment options. Whilst bispho-
sphonates are currently the most widely used bone protec-
tive drugs in individuals taking glucocorticoids, the use of
teriparatide and of denosumab (if approved) as ﬁrst-line
options in some patients merits further investigation.
Finally, the potential for sclerostin inhibitors to prevent or
reverse adverse skeletal effects of glucocorticoids provides
an exciting prospect for future research.
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